Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study DOI Creative Commons

Jiajin Yang,

Qiuping Xu,

Sihao Luo

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 16, 2025

This study evaluated the effectiveness and safety of tislelizumab plus lenvatinib (TL group) monotherapy (T in patients with stage C hepatocellular carcinoma (HCC) according to Barcelona Clinic Liver Cancer (BCLC) staging system after failure, it analyzed factors influencing TL as a second-line treatment. retrospective analysis involved 51 treated at single center between January 2019 July 2023. Survival outcomes tumor responses were compared T groups. Prognostic for overall survival (OS) progression-free (PFS) identified using Cox proportional hazard regression models. Among BCLC advanced HCC who experienced treatment median PFS was significantly longer group than (6.8 months vs. 4.5 months, p = 0.003), OS notably extended (14.0 10.4 0.012). Although disease control rate (64% 53.8%, 0.461) objective response (20% 7.7%, 0.202) numerically higher group, these differences did not reach significance. Child-Pugh B liver function independent prognostic poor OS, whereas only an factor PFS, PFS. Subgroup demonstrated benefit A 12.0 0.013) but those (7.7 6.1 0.225). In most frequent treatment-related adverse events (AEs) hand-foot skin reaction (32%), hypertension (28%), diarrhea hypothyroidism (20%). Grade 3 or AEs occurred 24% grade AEs. The incidence comparable two As treatment, combination well tolerated associated improved versus alone HCC, particularly function.

Language: Английский

Clinically Evident Portal Hypertension Is an Independent Risk Factor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation DOI Open Access
A. Kornberg, Nick Seyfried,

Helmut Frieß

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2032 - 2032

Published: March 17, 2025

Background/Objectives: Clinically evident portal hypertension (CEPH) is a major risk factor for the development and poor outcomes of hepatocellular carcinoma (HCC). The aim this study was to determine impact CEPH on HCC recurrence following liver transplantation (LT). Methods: A total 129 patients were included in retrospective analysis. definition based indirect clinical features without hepatic venous pressure gradient measurement. post-LT determined by uni- multivariate Results: Evidence manifest (PH) associated with higher 18F-fluorodeoxy-glucose (FDG) uptake positron emission tomography (PET; p < 0.001) increased serum levels C-reactive protein (p = 0.008) interleukin−6 (IL-6; 0.001). cumulative at 5 years significantly group (38.1% vs. 10.6%, eligibility neoadjuvant transarterial chemoembolization (TACE) comparable between both cohorts (71.4% 74.2%; 0.719). However, post-interventional pathologic response rate lower case PH (15.6% 53.1%; In addition Milan criteria (MC), 18F-FDG avidity PET values IL-6 alfa-fetoprotein, we identified as another significant independent predictor 0.008). Conclusions: correlates an unfavorable tumor phenotype, TACE refractoriness recurrence. Therefore, should be implemented pre-transplant assessment decision-making processes.

Language: Английский

Citations

0
Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma DOI
Kyoko Oura, Asahiro Morishita,

Rie Yano

et al.

Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Language: Английский

Citations

0
Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study DOI Creative Commons

Jiajin Yang,

Qiuping Xu,

Sihao Luo

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 16, 2025

This study evaluated the effectiveness and safety of tislelizumab plus lenvatinib (TL group) monotherapy (T in patients with stage C hepatocellular carcinoma (HCC) according to Barcelona Clinic Liver Cancer (BCLC) staging system after failure, it analyzed factors influencing TL as a second-line treatment. retrospective analysis involved 51 treated at single center between January 2019 July 2023. Survival outcomes tumor responses were compared T groups. Prognostic for overall survival (OS) progression-free (PFS) identified using Cox proportional hazard regression models. Among BCLC advanced HCC who experienced treatment median PFS was significantly longer group than (6.8 months vs. 4.5 months, p = 0.003), OS notably extended (14.0 10.4 0.012). Although disease control rate (64% 53.8%, 0.461) objective response (20% 7.7%, 0.202) numerically higher group, these differences did not reach significance. Child-Pugh B liver function independent prognostic poor OS, whereas only an factor PFS, PFS. Subgroup demonstrated benefit A 12.0 0.013) but those (7.7 6.1 0.225). In most frequent treatment-related adverse events (AEs) hand-foot skin reaction (32%), hypertension (28%), diarrhea hypothyroidism (20%). Grade 3 or AEs occurred 24% grade AEs. The incidence comparable two As treatment, combination well tolerated associated improved versus alone HCC, particularly function.

Language: Английский

Citations

0